Polycythemia Vera Medical Services in China

Polycythemia Vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by the overproduction of red blood cells (erythrocytosis), often accompanied by elevated white blood cell and platelet counts. It arises from a somatic gain-of-function mutation in the JAK2 gene—most commonly JAK2 V617F—in hematopoietic stem cells, leading to cytokine-independent activation of the JAK-STAT signaling pathway. This results in uncontrolled proliferation of erythroid precursors in the bone marrow, independent of erythropoietin (EPO) regulation. PV is not inherited but acquired, and while its exact triggers remain unclear, aging is the strongest known risk factor; the median age at diagnosis is 60–65 years. Epidemiologically, PV has an annual incidence of approximately 0.4–2.8 cases per 100,000 people, with a slight male predominance (male-to-female ratio ~1.3:1). It is rare in children and adolescents. Risk factors include advanced age, prior exposure to ionizing radiation (limited evidence), and possibly certain occupational chemical exposures—though no definitive environmental or lifestyle modifiable risks have been established. Untreated PV significantly increases the risk of life-threatening thrombotic events—including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke—as well as hemorrhagic complications, transformation to myelofibrosis (5–15% over 15 years), and acute myeloid leukemia (1–2% over 10 years). Symptoms are often insidious and nonspecific: headache, dizziness, visual disturbances (e.g., scintillating scotoma), pruritus (especially after warm showers), erythromelalgia (burning pain in hands/feet), fatigue, early satiety, and splenomegaly-related left upper quadrant discomfort. Many patients are asymptomatic at diagnosis and identified incidentally via routine blood tests showing elevated hemoglobin (>16.5 g/dL in men, >16.0 g/dL in women), hematocrit (>49% in men, >48% in women), and/or red blood cell mass. Quality of life is frequently impaired—not only by physical symptoms but also by anxiety related to thrombotic risk, treatment burden (e.g., lifelong phlebotomy, medication adherence), and psychosocial impact of a chronic hematologic malignancy. Fatigue remains one of the most prevalent and debilitating patient-reported outcomes, even in well-controlled disease. Effective management aims to reduce thrombotic risk through cytoreduction, symptom control, and vigilant monitoring for disease progression. Early diagnosis and individualized, long-term care by specialized hematologists are essential to preserve survival (median overall survival exceeds 14–20 years with modern therapy) and maintain functional quality of life.

Polycythemia vera (PV) is a chronic, clonal myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, often accompanied by increased white blood cell and platelet counts. It arises from a somatic mutation in a hematopoietic stem cell, leading to cytokine-independent proliferation of erythroid, granulocytic, and megakaryocytic lineages. The hallmark genetic abnormality is the JAK2 V617F mutation, present in approximately 95% of PV patients. This gain-of-function mutation results in constitutive activation of the JAK-STAT signaling pathway, driving uncontrolled erythropoiesis without physiological erythropoietin (EPO) stimulation. In the remaining 3–5% of cases, PV is associated with exon 12 mutations in the JAK2 gene, which similarly confer ligand-independent activation but typically present with isolated erythrocytosis and lower leukocyte/platelet counts. Rarely, mutations in other genes—including TET2, ASXL1, DNMT3A, and IDH1/2—may co-occur as secondary or subclonal events, contributing to disease heterogeneity, progression risk, and clonal evolution. Importantly, PV is not inherited; all causative mutations are acquired post-zygotically and are not transmitted to offspring.

No definitive environmental triggers cause PV, and no exogenous exposures have been consistently validated as etiologic agents. Unlike some hematologic malignancies, PV shows no established association with ionizing radiation, chemotherapy, benzene, or other industrial toxins. Epidemiologic studies have failed to demonstrate reproducible links to occupational hazards, dietary factors, infections, or lifestyle variables such as smoking or alcohol use. However, certain conditions may unmask or exacerbate underlying PV. For example, chronic hypoxia (e.g., due to severe COPD, high-altitude residence, or sleep apnea) can stimulate physiologic erythropoiesis and complicate the differential diagnosis—but it does not trigger PV itself. Similarly, testosterone therapy or erythropoietin misuse may induce secondary erythrocytosis that mimics PV clinically, necessitating careful diagnostic evaluation including serum EPO measurement and JAK2 testing.

Established risk factors for PV are primarily demographic and clinical. Age is the strongest non-genetic risk factor: median age at diagnosis is 60–65 years, and incidence rises sharply after age 50; pediatric cases are exceedingly rare. Males are affected slightly more frequently than females (male-to-female ratio ~1.2–1.4:1), though the biological basis remains unclear. There is no robust evidence supporting familial clustering beyond rare instances of germline predisposition variants (e.g., in JAK2 or TERT promoter regions), which may modestly increase susceptibility but are neither necessary nor sufficient for PV development. Comorbidities such as hypertension, diabetes mellitus, and hyperlipidemia do not cause PV but significantly amplify thrombotic risk—the leading cause of morbidity and mortality in PV. Prior history of venous or arterial thrombosis, advanced age (>60 years), and leukocytosis (>15 × 10⁹/L) are validated predictors of future thrombosis and guide risk stratification and therapeutic intensity. Splenomegaly at diagnosis correlates with higher allele burden and disease burden, while elevated lactate dehydrogenase (LDH) and low erythropoietin levels support clonality but are not causal factors.

Genetic predisposition plays a minimal direct role; PV is overwhelmingly sporadic. Genome-wide association studies (GWAS) have identified common low-penetrance polymorphisms near JAK2 (e.g., rs10974944, rs12343867) that modestly increase lifetime risk (~1.5–2-fold), likely by influencing JAK2 expression or mutational susceptibility in hematopoietic precursors. These variants are prevalent in the general population and insufficient to cause disease without acquisition of the driver mutation. Epigenetic dysregulation—including aberrant DNA methylation and histone modification—emerges during disease progression and may facilitate transformation to post-PV myelofibrosis or acute myeloid leukemia, but these changes are consequences rather than causes of clonal expansion.

In summary, PV is fundamentally driven by acquired somatic mutations activating JAK-STAT signaling, with JAK2 V617F being central. No environmental exposures are causally implicated. Risk is predominantly determined by age, sex, and molecular features—not modifiable lifestyle or external factors. Accurate diagnosis hinges on integrating clinical presentation, laboratory findings (elevated hemoglobin/hematocrit, low serum EPO), bone marrow morphology, and molecular testing. Understanding these etiologic and risk elements is essential for appropriate classification, prognostication, and targeted management in hematology practice.

Polycythemia vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by autonomous overproduction of red blood cells (erythrocytosis), often accompanied by leukocytosis and thrombocytosis. It arises from a somatic gain-of-function mutation in the JAK2 gene—most commonly JAK2 V617F—in hematopoietic stem cells, leading to cytokine-independent activation of the JAK-STAT signaling pathway. PV predominantly affects individuals aged 60–70 years, with a slight male predominance, and carries significant morbidity and mortality primarily due to thrombotic and hemorrhagic complications.

Early symptoms are frequently nonspecific and insidious, often overlooked or misattributed to aging or stress. Patients may report persistent fatigue, unexplained lethargy, generalized weakness, and diminished exercise tolerance—reflecting tissue hyperviscosity and impaired microcirculatory flow. Pruritus, particularly aquagenic pruritus (intense itching triggered by warm water exposure, e.g., showering), is a highly characteristic early symptom occurring in up to 40% of patients and results from aberrant mast cell activation and histamine release. Early neurologic manifestations include lightheadedness, dizziness, headache, tinnitus, visual disturbances (e.g., scintillating scotomata), and transient ischemic attacks (TIAs)—all attributable to cerebral hyperviscosity and microvascular stasis. Approximately 20–30% of patients experience early vasomotor symptoms such as facial flushing (plethora), erythromelalgia (burning pain, warmth, and redness in hands and feet), and digital ischemia, reflecting platelet hyperreactivity and microvascular thrombosis.

Typical symptoms evolve as hematocrit rises (>49% in men, >48% in women) and blood viscosity increases. Marked splenomegaly develops in ~75% of patients, often causing left upper quadrant discomfort, early satiety, or postprandial abdominal fullness due to gastric compression. Hepatomegaly is present in ~40% and may contribute to right upper quadrant discomfort. Patients commonly describe a sensation of 'fullness' or pressure in the head, neck, or abdomen. Thrombotic events—both arterial and venous—are hallmark clinical presentations: myocardial infarction, ischemic stroke, deep vein thrombosis (DVT), splanchnic vein thrombosis (e.g., Budd-Chiari syndrome, portal vein thrombosis), and retinal vein occlusion occur in up to 35% of untreated patients and represent the leading cause of death. Hemorrhagic manifestations—including epistaxis, gingival bleeding, easy bruising, and gastrointestinal bleeding—arise from acquired von Willebrand syndrome (due to proteolysis of high-molecular-weight vWF multimers by increased platelet-associated ADAMTS13 activity) and platelet dysfunction.

Accompanying symptoms reflect systemic inflammation and clonal burden. Low-grade fever, night sweats, and unintentional weight loss (>10% body weight over 6 months) constitute B symptoms and suggest disease progression or transformation. Gout and uric acid nephropathy occur secondary to increased cell turnover and purine catabolism; hyperuricemia is present in ~30% at diagnosis. Microvascular disturbances may manifest as acrocyanosis, livedo reticularis, or digital ulceration. Some patients develop erythromelalgic crises—acute, severe burning pain with erythema and edema in distal extremities—requiring urgent cytoreduction. Cognitive complaints ('brain fog'), depression, and sleep disturbances are increasingly recognized as part of the PV symptom burden and correlate with inflammatory cytokine elevation (e.g., IL-6, TNF-α).

Complications extend beyond thrombosis and hemorrhage. Myelofibrotic transformation occurs in ~10–15% of patients after 10–15 years, presenting with worsening anemia, progressive splenomegaly, constitutional symptoms, and teardrop poikilocytes on peripheral smear. Acute myeloid leukemia (AML) develops in 2–5% of patients, typically after prolonged exposure to alkylating agents (e.g., pipobroman, busulfan) or radioactive phosphorus (32P); risk is lower with hydroxyurea or interferon-based regimens. Splanchnic vein thrombosis—particularly Budd-Chiari syndrome—is highly suggestive of PV and warrants immediate evaluation even in the absence of overt erythrocytosis. Pulmonary hypertension may develop secondary to chronic hypoxia from sleep apnea (exacerbated by polycythemia) or direct pulmonary vascular remodeling. Iron deficiency—anemia paradoxically emerges in up to 50% of patients due to chronic phlebotomy, menstrual losses, or gastrointestinal bleeding—and can mask true hematocrit elevation, complicating monitoring.

Diagnosis relies on integration of clinical, laboratory, and molecular criteria per the World Health Organization (WHO) 2022 classification. Major criteria include: (1) hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women), or hematocrit >49% (men) or >48% (women), or red blood cell mass increased by >25% above mean predicted value; (2) presence of JAK2 V617F or JAK2 exon 12 mutation; and (3) subnormal serum erythropoietin (EPO) level. Minor criteria include bone marrow biopsy showing panmyelosis with prominent erythroid, granulocytic, and megakaryocytic proliferation and pleomorphic megakaryocytes, and endogenous erythroid colony (EEC) formation in vitro. Diagnosis requires either all three major criteria or the first two major plus the minor criterion. Serum EPO measurement is mandatory to exclude secondary erythrocytosis. Bone marrow biopsy is recommended in all suspected cases to assess morphology, fibrosis grade, and rule out other MPNs or myeloid malignancies. Additional testing includes comprehensive metabolic panel (to assess renal function, uric acid, LDH), lactate dehydrogenase (LDH), ferritin, iron studies, arterial blood gas (to exclude hypoxia), and imaging (e.g., Doppler ultrasound for splanchnic veins, echocardiogram if pulmonary hypertension suspected).

Differential diagnosis is critical to avoid mismanagement. Secondary erythrocytosis must be excluded: causes include chronic hypoxia (e.g., COPD, sleep apnea, high-altitude residence), renal disorders (e.g., renal artery stenosis, renal cell carcinoma, cysts), endocrine tumors (e.g., pheochromocytoma, hepatocellular carcinoma), and exogenous EPO administration. Familial erythrocytosis (e.g., mutations in EPOR, VHL, PHD2, HIF2A) presents with normal or elevated EPO and absence of JAK2 mutations. Other myeloproliferative neoplasms require distinction: essential thrombocythemia (ET) features isolated thrombocytosis without erythrocytosis or JAK2 V617F-driven erythroid expansion; primary myelofibrosis (PMF) shows marked fibrosis, anemia, and teardrop cells, often with leukoerythroblastosis. Chronic myeloid leukemia (CML) is distinguished by BCR-ABL1 fusion gene detection. Reactive thrombocytosis and leukocytosis (e.g., infection, inflammation, iron deficiency) lack clonal markers and resolve with treatment of the underlying condition. Finally, masked PV—characterized by near-normal hematocrit due to concomitant iron deficiency—must be considered when JAK2 mutation is detected despite borderline hemoglobin values; iron repletion may unmask erythrocytosis.

Polycythemia vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by autonomous overproduction of red blood cells, often accompanied by elevated white blood cell and platelet counts. Driven predominantly by the JAK2 V617F mutation (>95% of cases), PV carries significant risks of thrombosis, hemorrhage, myelofibrosis transformation, and acute leukemia. Management in the Department of Hematology focuses on risk stratification—based on age (>60 years) and prior thrombotic history—and tailoring interventions to reduce morbidity and mortality while preserving quality of life.

Conservative treatment forms the cornerstone of initial management, particularly for low-risk patients (age <60 years, no prior thrombosis). Phlebotomy remains first-line: regular venesection (typically 250–500 mL every 2–4 days initially) aims to maintain hematocrit <45% in men and <42% in women. This rapidly reduces blood viscosity, lowers thrombotic risk, and alleviates symptoms such as headache, dizziness, pruritus, and erythromelalgia. Aspirin (low-dose, 75–100 mg daily) is universally recommended for all PV patients without contraindications (e.g., active peptic ulcer disease or severe bleeding diathesis), as it significantly reduces microvascular complications—including transient ischemic attacks, digital ischemia, and ocular migraines—by inhibiting platelet cyclooxygenase-1. Lifestyle modifications are integral: smoking cessation is non-negotiable due to synergistic endothelial injury; hydration must be optimized to prevent hemoconcentration; and patients are counseled on early recognition of thrombotic symptoms (e.g., unilateral leg swelling, chest pain, sudden dysarthria) and hemorrhagic signs (e.g., prolonged epistaxis, petechiae).

Pharmacologic therapy is indicated for high-risk patients and those intolerant or refractory to phlebotomy alone. Hydroxyurea, a ribonucleotide reductase inhibitor, is the most widely used cytoreductive agent. It effectively controls hematocrit, leukocyte, and platelet counts, reduces splenomegaly, and lowers thrombotic incidence. Dosing is individualized (typically 500–2000 mg/day), with close monitoring of complete blood count and liver enzymes. Long-term safety is well-established, though rare concerns include cutaneous ulcers and potential (though unproven in large cohort studies) leukemogenicity after decades of use. For hydroxyurea-intolerant or resistant patients—or those with marked thrombocytosis (>1,500 × 10⁹/L) and microvascular symptoms—interferon-alpha (IFN-α), particularly pegylated formulations (peg-IFN-α-2a or -2b), offers a targeted, non-leukemogenic alternative. IFN-α induces molecular responses in up to 20–30% of patients (reduction in JAK2 V617F allele burden) and may modify disease biology. Ruxolitinib, a JAK1/JAK2 inhibitor, is FDA- and EMA-approved for hydroxyurea-resistant/intolerant PV. It provides robust control of splenomegaly and constitutional symptoms (fatigue, night sweats, weight loss) and improves hematocrit control, though it does not eliminate the malignant clone and requires vigilant monitoring for cytopenias and herpes zoster reactivation. Anagrelide may be added selectively for extreme thrombocytosis but is avoided as monotherapy due to increased arterial thrombosis risk and lack of benefit on erythrocytosis.

Surgical treatment has no primary role in PV management. Splenectomy is rarely performed—only in exceptional circumstances such as life-threatening portal vein thrombosis with massive, painful splenomegaly refractory to medical therapy—but carries high perioperative thrombotic and infectious risks and is associated with accelerated bone marrow fibrosis. Therefore, it is considered a last-resort palliative measure and is not part of standard guidelines. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative modality but is reserved exclusively for select younger patients (<50–55 years) with progressive post-PV myelofibrosis or blast-phase transformation, given its substantial treatment-related mortality (15–30%) and morbidity. Its use in chronic-phase PV is not justified outside clinical trials due to favorable long-term survival with modern pharmacotherapy.

Treatment advantages in China reflect rapid integration of international standards with localized innovations. Major academic centers—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and the First Affiliated Hospital of Sun Yat-sen University—offer comprehensive molecular diagnostics (JAK2/CALR/MPL sequencing, next-generation sequencing panels), standardized phlebotomy protocols, and access to biosimilar hydroxyurea and pegylated interferons at substantially lower cost than in Western markets. Notably, China’s National Medical Products Administration (NMPA) has approved ruxolitinib for PV since 2021, and real-world evidence from multicenter registries demonstrates comparable efficacy and safety to global data. Furthermore, China leads in digital health infrastructure: AI-powered decision support tools assist hematologists in dynamic risk assessment and treatment escalation, while telemonitoring platforms enable remote hematocrit tracking and symptom reporting—enhancing adherence and early intervention. Clinical trial participation is robust, with Chinese sites contributing significantly to pivotal phase III studies of novel agents (e.g., rusfertide, a hepcidin mimetic in late-stage development).

Recovery and long-term follow-up emphasize proactive, lifelong engagement. Patients require quarterly clinical assessments—including physical exam (spleen size), CBC, LDH, uric acid, and ferritin—plus annual bone marrow evaluation only if cytopenias, increasing splenomegaly, or worsening symptoms suggest progression. Iron deficiency induced by repeated phlebotomy must be monitored (serum ferritin <30 ng/mL warrants cautious iron supplementation only if symptomatic anemia develops, as excess iron may paradoxically stimulate erythropoiesis). Vaccination against influenza, pneumococcus, and hepatitis B is strongly encouraged due to immune dysregulation and splenic hypofunction in advanced disease. Psychosocial support is vital: chronic PV correlates with elevated anxiety and fatigue burden; multidisciplinary clinics increasingly incorporate psycho-oncology services and peer-led support networks. Finally, reproductive counseling is essential for premenopausal women—hydroxyurea is teratogenic, requiring contraception during treatment and for three months post-discontinuation; pregnancy necessitates transition to low-molecular-weight heparin and aspirin under joint hematology-obstetrics care. With contemporary risk-adapted strategies, median survival exceeds 20 years, underscoring that PV is a highly manageable chronic condition when managed by specialized hematologists within integrated, patient-centered systems.